文献速递免疫规划卫生政策与健康促进

疫苗决策者与研究者对卫生经济学报告格式的偏好调查

Preferences for health economics presentations among vaccine policymakers and researchers.
PubMed 文献 · Vaccine · 2018-09-17

研究通过关键知情人访谈和在线调查,了解免疫实践咨询委员会(ACIP)相关决策者与研究者对卫生经济学报告格式的偏好。最佳-最差量表调查应答率51%(n=93),汇总结果被视为决策中最重要的属性(平均重要性评分0.69),中间结局和分解结果最不重要(-0.71)。关键知情人访谈提出应增加分析质量信息并提升熟悉卫生经济学联络员的作用。

要点

  • 汇总结果平均重要性评分0.69,为决策中最重要的报告属性。
  • 中间结局与分解结果平均重要性评分为-0.71,为最不重要的属性。
  • 无卫生经济学经验者较有经验者更重视结果与其他研究的关系(0.13 vs -0.12)。

核心结论

  • 卫生经济学报告增加更多具体信息可能有助于更有效地呈现疫苗决策证据。

研究设计与样本

  • 研究采用关键知情人访谈和在线调查,对象为现任ACIP工作组成员、现任及前任ACIP投票成员、联络代表和当然成员。
  • 调查使用最佳-最差量表测量卫生经济学报告七个属性在疫苗决策中的相对价值,应答率51%(n=93)。

主要发现

  • 汇总结果的平均重要性评分为0.69,为决策中最重要的属性;中间结局和分解结果的平均重要性评分为-0.71,为最不重要的属性。
  • 无卫生经济学经验组对敏感性分析的重要性评分低于有经验组(-0.15 vs 0.15),对结果与其他研究关系的重要性评分高于有经验组(0.13 vs -0.12)。
  • 关键知情人访谈确定需改进的方面包括增加分析质量的信息以及提升熟悉卫生经济学的联络员的作用。

关键数值与推荐

  • 最佳-最差量表调查应答率为51%(n=93)。
  • 汇总结果平均重要性评分为0.69,中间结局和分解结果平均重要性评分为-0.71。
  • 无经验组敏感性分析评分-0.15,有经验组0.15;无经验组结果与其他研究关系评分0.13,有经验组-0.12。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Measure the preferences of decision makers and researchers associated with the Advisory Committee on Immunization Practices (ACIP) regarding the recommended format for presenting health economics studies to the ACIP. METHODS: We conducted key informant interviews and an online survey of current ACIP work group members, and current and previous ACIP voting members, liaison representatives, and ex-officio members to understand preferences for health economics presentations. These preferences included the presentation of results and sensitivity analyses, the role of health economics studies in decision making, and strategies to improve guidelines for presenting health economics studies. Best-worst scaling was used to measure the relative value of seven attributes of health economics presentations in vaccine decision making. RESULTS: The best-worst scaling survey had a response rate of 51% (n = 93). Results showed that summary results were the most important attribute for decision making (mean importance score: 0.69) and intermediate outcomes and disaggregated results were least important (mean importance score: -0.71). Respondents without previous health economics experience assigned sensitivity analysis lower importance and relationship of the results to other studies higher importance than the experienced group (sensitivity analysis scores: -0.15 vs. 0.15 respectively; relationship of the results: 0.13 vs. -0.12 respectively). Key informant interviews identified areas for improvement to include additional information on the quality of the analysis and increased role for liaisons familiar with health economics. CONCLUSION: Additional specificity in health economics presentations could allow for more effective presentations of evidence for vaccine decision making.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Richardson JS, Messonnier ML, Prosser LA, et al. Preferences for health economics presentations among vaccine policymakers and researchers. Vaccine. 2018. PMID: 30236631. doi:10.1016/j.vaccine.2018.08.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。